Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Badges Review

Behçet's disease

Shunsei Hirohata* and Hirotoshi Kikuchi

Author affiliations

Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan

For all author emails, please log on.

Citation and License

Arthritis Res Ther 2003, 5:139-146  doi:10.1186/ar757

Published: 2 April 2003


Behçet's disease is characterized by recurrent aphthous stomatitis, uveitis, genital ulcers, and skin lesions. The role of the HLA-B*51 gene has been confirmed in recent years, although its contribution to the overall genetic susceptibility to Behçet's disease was estimated to be only 19%. The production of a variety of cytokines by T cells activated with multiple antigens has been shown to play a pivotal role in the activation of neutrophils. As regards the treatment, anti-tumor necrosis factor alpha therapy has been shown to be effective for mucocutaneous symptoms as well as for sight-threatening panuveitis, although a randomized, controlled trial is required.

HLA-B51; neutrophil; T lymphocytes; treatment; tumor necrosis factor alpha